Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

• PubMed
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.)| false
• Search Google Scholar
• Export Citation

Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:23–33.

• PubMed
Eichhorst B, Robak T, Montserrat E, Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:23–33.)| false
• Search Google Scholar
• Export Citation

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745–2760.

• PubMed
Hallek M, Cheson BD, Catovsky D, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745–2760.)| false
• Search Google Scholar
• Export Citation

Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 2017;178:394–402.

• PubMed
Strati P, Parikh SA, Chaffee KG, Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 2017;178:394–402.)| false
• Search Google Scholar
• Export Citation

Muthiah C, Narra R, Atallah E, et al. Evaluating population-level outcomes in chronic lymphocytic leukemia in the era of novel therapies using the SEER registry. Leuk Res 2024;140:107496.

• PubMed
Muthiah C, Narra R, Atallah E, Evaluating population-level outcomes in chronic lymphocytic leukemia in the era of novel therapies using the SEER registry. Leuk Res 2024;140:107496.)| false
• Search Google Scholar
• Export Citation

Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015;126:573–581.

• PubMed
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015;126:573–581.)| false
• Search Google Scholar
• Export Citation

Svanberg Teglgaard R, Marquart HV, Hartling HJ, et al. Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials. Clin Cancer Res 2024;30:1959–1971.

• PubMed
Svanberg Teglgaard R, Marquart HV, Hartling HJ, Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials. Clin Cancer Res 2024;30:1959–1971.)| false
• Search Google Scholar
• Export Citation

Purroy N, Tong YE, Lemvigh CK, et al. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood 2022;139:2252–2256.

• PubMed
Purroy N, Tong YE, Lemvigh CK, Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood 2022;139:2252–2256.)| false
• Search Google Scholar
• Export Citation

Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592–601.

• PubMed
Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592–601.)| false
• Search Google Scholar
• Export Citation

Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200–2206.

• PubMed
Furman RR, Asgary Z, Mascarenhas JO, Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200–2206.)| false
• Search Google Scholar
• Export Citation

Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173–206.

• PubMed
Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173–206.)| false
• Search Google Scholar
• Export Citation

Shain K, Dalton W, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015;34:4673–4682.

• PubMed
Shain K, Dalton W, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015;34:4673–4682.)| false
• Search Google Scholar
• Export Citation

Dubois N, Crompot E, Meuleman N, et al. Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles. Front Oncol 2020;10:1422.

• PubMed
Dubois N, Crompot E, Meuleman N, Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles. Front Oncol 2020;10:1422.)| false
• Search Google Scholar
• Export Citation

Landeira-Viñuela A, Arias-Hidalgo C, Juanes-Velasco P, et al. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: physiological immunomodulators or immune dysfunction. Front Immunol 2022;13:965905.

• PubMed
Landeira-Viñuela A, Arias-Hidalgo C, Juanes-Velasco P, Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: physiological immunomodulators or immune dysfunction. Front Immunol 2022;13:965905.)| false
• Search Google Scholar
• Export Citation

DiLillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013;27:170–182.

• PubMed
DiLillo DJ, Weinberg JB, Yoshizaki A, Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013;27:170–182.)| false
• Search Google Scholar
• Export Citation

Garaud S, Morva A, Lemoine S, et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011;186:4835–4844.

• PubMed
Garaud S, Morva A, Lemoine S, CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011;186:4835–4844.)| false
• Search Google Scholar
• Export Citation

Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165–3173.

• PubMed
Herishanu Y, Avivi I, Aharon A, Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165–3173.)| false
• Search Google Scholar
• Export Citation

Whitaker JA, Parikh SA, Shanafelt TD, et al. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine 2021;39:1122–1130.

• PubMed
Whitaker JA, Parikh SA, Shanafelt TD, The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine 2021;39:1122–1130.)| false
• Search Google Scholar
• Export Citation

Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403–1413.

• PubMed
Ghia P, Strola G, Granziero L, Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403–1413.)| false
• Search Google Scholar
• Export Citation

Zaaboub R, Vimeux L, Contremoulins V, et al. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21. Blood Adv 2022;6:4691–4704.

• PubMed
Zaaboub R, Vimeux L, Contremoulins V, Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21. Blood Adv 2022;6:4691–4704.)| false
• Search Google Scholar
• Export Citation

Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017;102:562–572.

• PubMed
Palma M, Gentilcore G, Heimersson K, T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017;102:562–572.)| false
• Search Google Scholar
• Export Citation

Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120:1412–1421.

• PubMed
Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120:1412–1421.)| false
• Search Google Scholar
• Export Citation

Mpakou VE, Ioannidou HD, Konsta E, et al. Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. Leuk Res 2017;60:74–81.

• PubMed
Mpakou VE, Ioannidou HD, Konsta E, Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. Leuk Res 2017;60:74–81.)| false
• Search Google Scholar
• Export Citation

Jak M, Mous R, Remmerswaal E, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.

• PubMed
Jak M, Mous R, Remmerswaal E, Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.)| false
• Search Google Scholar
• Export Citation

Gustafson MP, Abraham RS, Lin Y, et al. Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012;156:674–676.

• PubMed
Gustafson MP, Abraham RS, Lin Y, Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012;156:674–676.)| false
• Search Google Scholar
• Export Citation

Talbot H, Saada S, Barthout E, et al. BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells. Sci Rep 2020;10:12572.

• PubMed
Talbot H, Saada S, Barthout E, BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells. Sci Rep 2020;10:12572.)| false
• Search Google Scholar
• Export Citation

Sourmerai J, Yousif Z, Gift T, et al. Patterns of IgG testing and rates of hypogammaglobulinemia in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Clin Immunol 2023;250:109601.

• PubMed
Sourmerai J, Yousif Z, Gift T, Patterns of IgG testing and rates of hypogammaglobulinemia in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Clin Immunol 2023;250:109601.)| false
• Search Google Scholar
• Export Citation

Ishdorj G, Streu E, Lambert P, et al. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv 2019;3:2188–2198.

• PubMed
Ishdorj G, Streu E, Lambert P, IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv 2019;3:2188–2198.)| false
• Search Google Scholar
• Export Citation

Andersen MA, Eriksen CT, Brieghel C, et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica 2018;103:e300–303.

• PubMed
Andersen MA, Eriksen CT, Brieghel C, Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica 2018;103:e300–303.)| false
• Search Google Scholar
• Export Citation

Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015;126:2213–2219.

• PubMed
Sun C, Tian X, Lee YS, Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015;126:2213–2219.)| false
• Search Google Scholar
• Export Citation

Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004;173:3901–3908.

• PubMed
Arens R, Nolte MA, Tesselaar K, Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004;173:3901–3908.)| false
• Search Google Scholar
• Export Citation

Sampalo A, Navas G, Medina F, et al. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96:3168–3174.

• PubMed
Sampalo A, Navas G, Medina F, Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96:3168–3174.)| false
• Search Google Scholar
• Export Citation

Else M, Blakemore SJ, Strefford JC, Catovsky D. The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. Leukemia 2021;35:2563–2569.

• PubMed
Else M, Blakemore SJ, Strefford JC, Catovsky D. The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. Leukemia 2021;35:2563–2569.)| false
• Search Google Scholar
• Export Citation

Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 1993;78:374–377.

• PubMed
Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 1993;78:374–377.)| false
• Search Google Scholar
• Export Citation

Soumerai J, Gift T, Yousif Z, et al. Infection outcomes and hypogammaglobulinemia in patients with chronic lymphocytic leukemia treated with immunoglobulin replacement therapy. Blood 2023;142:3280.

• PubMed
Soumerai J, Gift T, Yousif Z, Infection outcomes and hypogammaglobulinemia in patients with chronic lymphocytic leukemia treated with immunoglobulin replacement therapy. Blood 2023;142:3280.)| false
• Search Google Scholar
• Export Citation

Bange EM, Han NA, Wileyto P, et al. CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Res Sq. Preprint posted online February 2, 2021. doi: 10.21203/rs.3.rs-162289/v1

• PubMed
Bange EM, Han NA, Wileyto P, CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Res Sq. Preprint posted online February 2, 2021. doi: 10.21203/rs.3.rs-162289/v1)| false
• Search Google Scholar
• Export Citation

Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612–1621.

• PubMed
Riches JC, Davies JK, McClanahan F, T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612–1621.)| false
• Search Google Scholar
• Export Citation

Moreno C, Solman IG, Tam CS, et al. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv 2023;7:5294–5303.

• PubMed
Moreno C, Solman IG, Tam CS, Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv 2023;7:5294–5303.)| false
• Search Google Scholar
• Export Citation

Davis JE, Handunnetti SM, Ludford-Menting M, et al. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv 2020;4:4849–4859.

• PubMed
Davis JE, Handunnetti SM, Ludford-Menting M, Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv 2020;4:4849–4859.)| false
• Search Google Scholar
• Export Citation

Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975;232:267–269.

• PubMed
Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975;232:267–269.)| false
• Search Google Scholar
• Export Citation

Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 2020;34:3197–3205.

• PubMed
Bond DA, Huang Y, Fisher JL, Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 2020;34:3197–3205.)| false
• Search Google Scholar
• Export Citation

Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904–910.

• PubMed
Tsimberidou AM, Wen S, McLaughlin P, Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904–910.)| false
• Search Google Scholar
• Export Citation

Kumar V, Ailawadhi S, Bojanini L, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J 2019;9:75.

• PubMed
Kumar V, Ailawadhi S, Bojanini L, Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J 2019;9:75.)| false
• Search Google Scholar
• Export Citation

Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016;30:331–336.

• PubMed
Solomon BM, Chaffee KG, Moreira J, Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016;30:331–336.)| false
• Search Google Scholar
• Export Citation

Shen Y, Coyle L, Kerridge I, et al. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter’s syndrome. EJHaem 2022;3:129–138.

• PubMed
Shen Y, Coyle L, Kerridge I, Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter’s syndrome. EJHaem 2022;3:129–138.)| false
• Search Google Scholar
• Export Citation

Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 2023;14:2147.

• PubMed
Al-Sawaf O, Zhang C, Jin HY, Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 2023;14:2147.)| false
• Search Google Scholar
• Export Citation

Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019;133:2031–2042.

• PubMed
Byrd JC, Hillmen P, O’Brien S, Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019;133:2031–2042.)| false
• Search Google Scholar
• Export Citation

Solomon BM, Rabe KG, Slager SL, et al. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013;31:930–937.

• PubMed
Solomon BM, Rabe KG, Slager SL, Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013;31:930–937.)| false
• Search Google Scholar
• Export Citation

Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230–239.

• PubMed
Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230–239.)| false
• Search Google Scholar
• Export Citation

Cao L, Wang F, Du XY, et al. Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. Sci Rep 2020;10:16357.

• PubMed
Cao L, Wang F, Du XY, Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. Sci Rep 2020;10:16357.)| false
• Search Google Scholar
• Export Citation

Strati P, Nasr SH, Leung N, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 2015;100:1180–1188.

• PubMed
Strati P, Nasr SH, Leung N, Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 2015;100:1180–1188.)| false
• Search Google Scholar
• Export Citation

Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007–2015.

• PubMed
Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007–2015.)| false
• Search Google Scholar
• Export Citation

Borthakur G, O’Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab–incidence and predictors. Br J Haematol 2007;136:800–805.

• PubMed
Borthakur G, O’Brien S, Wierda WG, Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab–incidence and predictors. Br J Haematol 2007;136:800–805.)| false
• Search Google Scholar
• Export Citation

Wang KY, Shah P, Skavla B, et al. Vaccination efficacy in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2023;64:42–56.

• PubMed
Wang KY, Shah P, Skavla B, Vaccination efficacy in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2023;64:42–56.)| false
• Search Google Scholar
• Export Citation

Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia 2021;35:737–746.

• PubMed
Mauro FR, Giannarelli D, Galluzzo CM, Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia 2021;35:737–746.)| false
• Search Google Scholar
• Export Citation

Vijenthira A, Gong I, Betschel SD, et al. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 2021;5:2624–2643.

• PubMed
Vijenthira A, Gong I, Betschel SD, Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 2021;5:2624–2643.)| false
• Search Google Scholar
• Export Citation

Andrick B, Alwhaibi A, DeRemer DL, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol 2018;182:712–714.

• PubMed
Andrick B, Alwhaibi A, DeRemer DL, Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol 2018;182:712–714.)| false
• Search Google Scholar
• Export Citation

Ujjani C, Gooley TA, Spurgeon SE, et al. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv 2023;7:4728–4737.

• PubMed
Ujjani C, Gooley TA, Spurgeon SE, Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv 2023;7:4728–4737.)| false
• Search Google Scholar
• Export Citation

Qin K, Honjo K, Sherrill-Mix S, et al. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: a prospective cohort study. PLoS Med 2023;20:e1004157.

• PubMed
Qin K, Honjo K, Sherrill-Mix S, Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: a prospective cohort study. PLoS Med 2023;20:e1004157.)| false
• Search Google Scholar
• Export Citation

Baden LR, Swaminathan S, Almyroudis NG, et al. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 3.2024. To view the most recent version, visit https://www.nccn.org/

• PubMed
Baden LR, Swaminathan S, Almyroudis NG, NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 3.2024. To view the most recent version, visit https://www.nccn.org/)| false
• Search Google Scholar
• Export Citation

Wierda WG, Brown J, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2025. To view the most recent version, visit https://www.nccn.org/

• PubMed
Wierda WG, Brown J, Abramson JS, NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2025. To view the most recent version, visit https://www.nccn.org/)| false
• Search Google Scholar
• Export Citation

Gale RP, Chapel HM, Bunch C, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319:902–907.

• PubMed
Gale RP, Chapel HM, Bunch C, Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319:902–907.)| false
• Search Google Scholar
• Export Citation

Mustafa SS, Jamshed S, Vadamalai K, Ramsey A. Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia. PLoS One 2021;16:e0258529.

• PubMed
Mustafa SS, Jamshed S, Vadamalai K, Ramsey A. Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia. PLoS One 2021;16:e0258529.)| false
• Search Google Scholar
• Export Citation

Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278–1291.

• PubMed
Sharman JP, Egyed M, Jurczak W, Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278–1291.)| false
• Search Google Scholar
• Export Citation

Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022;23:1031–1043.

• PubMed
Tam CS, Brown JR, Kahl BS, Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022;23:1031–1043.)| false
• Search Google Scholar
• Export Citation

Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:1188–1200.

• PubMed
Al-Sawaf O, Zhang C, Tandon M, Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:1188–1200.)| false
• Search Google Scholar
• Export Citation

Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450–456.

• PubMed
Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450–456.)| false
• Search Google Scholar
• Export Citation

Arruga F, Gyau BB, Iannello A, et al. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci 2020;21:1825.

• PubMed
Arruga F, Gyau BB, Iannello A, Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci 2020;21:1825.)| false
• Search Google Scholar
• Export Citation

Jurado-Camino T, Cordoba R, Esteban-Burgos L, et al. Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J Immunol 2015;194:719–727.

• PubMed
Jurado-Camino T, Cordoba R, Esteban-Burgos L, Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J Immunol 2015;194:719–727.)| false
• Search Google Scholar
• Export Citation

Manukyan G, Papajik T, Gajdos P, et al. Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget 2017;8:84889–84901.

• PubMed
Manukyan G, Papajik T, Gajdos P, Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget 2017;8:84889–84901.)| false
• Search Google Scholar
• Export Citation

Toniolo PA, Liu S, Yeh JE, et al. Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget 2016;7:46301–46314.

• PubMed
Toniolo PA, Liu S, Yeh JE, Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget 2016;7:46301–46314.)| false
• Search Google Scholar
• Export Citation

MacFarlane IA, Jillab M, Smith MR, et al. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology 2017;6:e1330235.

• PubMed
MacFarlane IA, Jillab M, Smith MR, NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology 2017;6:e1330235.)| false
• Search Google Scholar
• Export Citation

Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 2021;35:3634–2024.

• PubMed
Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 2021;35:3634–2024.)| false
• Search Google Scholar
• Export Citation

Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 2018;131:2283–2296.

• PubMed
Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 2018;131:2283–2296.)| false
• Search Google Scholar
• Export Citation

Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127:3052–3064.

• PubMed
Long M, Beckwith K, Do P, Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127:3052–3064.)| false
• Search Google Scholar
• Export Citation

Zou YX, Zhu HY, Li XT, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematol Oncol 2019;37:392–400.

• PubMed
Zou YX, Zhu HY, Li XT, The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematol Oncol 2019;37:392–400.)| false
• Search Google Scholar
• Export Citation

Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor–microenvironment interactions by ibrutinib–findings from an investigator-initiated phase II study. Clin Cancer Res 2016;22:1572–1582.

• PubMed
Niemann CU, Herman SE, Maric I, Disruption of in vivo chronic lymphocytic leukemia tumor–microenvironment interactions by ibrutinib–findings from an investigator-initiated phase II study. Clin Cancer Res 2016;22:1572–1582.)| false
• Search Google Scholar
• Export Citation

de Weerdt I, Hofland T, de Boer R, et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv 2019;3:2642–2652.

• PubMed
de Weerdt I, Hofland T, de Boer R, Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv 2019;3:2642–2652.)| false
• Search Google Scholar
• Export Citation